Golimumab in psoriatic arthritis: One‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trial
Authors
Discussion
Loading...
Member takes
Implication
Randomized placebo-controlled trial demonstrates inhibited structural damage and sustained efficacy with golimumab in psoriatic arthritis, highlighting its long-term benefits.
Key Points
- To assess the one-year clinical efficacy, radiographic structural progression, and safety of golimumab in patients with active psoriatic arthritis.
- Conducted a phase III, randomized, placebo-controlled trial evaluating the therapeutic effects of golimumab through 1 year of treatment.
- Treatment with golimumab significantly inhibited the progression of radiographic structural damage through 1 year of follow-up.
- Golimumab maintained sustained clinical efficacy and demonstrated a consistent safety profile over the 1-year study duration.
Cite This Study
Kavanaugh et al. (2012) studied this question.